About

The CSF is an educational website developed under the auspices of the University of Glasgow and is dedicated to the dissemination of the latest developments in cytokine signalling. It provides continuing medical education to clinicians around the globe to facilitate greater understanding of the science of cytokines and cytokine signalling, and its implications for clinical practice.

CSF programmes are free from commercial bias, and feature leading experts sharing their knowledge and experience in the form of video tutorials.

EULAR 2023 Symposium
EULAR 2023 Webinar
Forum LIVE
Cytokine Signalling Forum
Discussing Rheumatology Podcasts

Publications

Free summaries and slides for a selection of papers

View and download slide summaries of the latest original articles focusing on cytokine signalling therapies within rheumatoid arthritis. All materials produced by the CSF team are subsequently reviewed and approved by individual steering committee members.

Podcasts

Listen on the go!

Here you will find a range of CSF podcasts recorded by our steering committee.

Congress Updates

The latest coverage of the biggest congresses in rheumatology

Coverage of key data relating to the science of cytokine signalling and new and developing therapeutic options that target cytokine signalling pathways presented at key congresses and reviewed for your information.

Online Educational Content

Free interactive tutorials, videos and assessments

A range of distance learning programmes to meet the educational need of healthcare professionals in achondroplasia. Key topics of interest have been identified through consultation and guidance from our Editorial Committee.

Latest Updates

Latest ▼
All

EULAR 2023 - CSF coverage highlights the most relevant data on RA, PsA, and axSpA. Including our Preview Brochures highlighting key posters and oral presentations ahead of the congress.

Discussing Rheumatology: May 2023

Publication thumbnail: Immunogenicity and Safety of Adjuvanted Recombinant Zoster Vaccine in Rheumatoid Arthritis Patients on Anti-Cellular Biologic Agents or JAK Inhibitors: A Prospective Observational Study

Immunogenicity and Safety of Adjuvanted Recombinant Zoster Vaccine in Rheumatoid Arthritis Patients on Anti-Cellular Biologic Agents or JAK Inhibitors: A Prospective Observational Study

Publication thumbnail: Evaluation of BMS-986142, a Reversible Bruton’s Tyrosine Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis: A Phase 2, Randomised, Double-blind, Dose-ranging, Placebo-controlled, Adaptive Design Study

Evaluation of BMS-986142, a Reversible Bruton’s Tyrosine Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis: A Phase 2, Randomised, Double-blind, Dose-ranging, Placebo-controlled, Adaptive Design Study

Steering Committee